BioLingus (Cayman) Limited (SUBL)

BioLingus (Cayman) Limited will go public soon, but the exact IPO date is still unknown.
IPO Price
$20.00
Shares Offered
360,000
Deal Size
$7.20M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 222.25M
Revenue (ttm) n/a
Net Income (ttm) -584,786
Shares Out 11.11M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SUBL

BioLingus in an exempted company with limited liability incorporated under the laws of the Cayman Islands, which is structured as a holding company whose main business operations are conducted through our subsidiaries in Switzerland and to a lesser extent, HK SAR, the People’s Republic of China and Australia. We are a biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins. The main peptide used to improve the technology was exenatide, which was the first commercial glucagon-like p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 15
Stock Exchange NASDAQ
Ticker Symbol SUBL
Full Company Profile

Financial Performance

Financial Statements

News

Biotech BioLingus files for IPO

BioLingus, a Swiss biotech company incorporated in the Cayman Islands, filed for an IPO on Friday. The company intends to trade on the Nasdaq Capital Market under the ticker symbol “SUBL.

8 months ago - Market Watch

BioLingus IPO Registration Document (F-1)

BioLingus has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC